Aptevo Therapeutics Inc APVO

Healthcare Biotechnology

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.

NDAQ:APVO - Post by User

Aptevo Therapeutics Inc > APVO..... This might sound familiar......

<< Previous

Bullboard Posts

Next >>

Comment by Iseneschalon Nov 26, 2021 10:00am

33 Views

Post# 34168448

RE:APVO..... This might sound familiar......

Iseneschal wrote: APVO has only traded just under 200 million shares in 2 trading days...

Remember what I said about .... Volume and Price action

Don't leave home without some....that's my mantra and IMHO

Cheers !

If you read between the lines......you could sense I was swinging APVO ; )

Yes....today was a big Cha Ching !!!!

Thanks for the dough !!!!

Cheers

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing